Visa is the largest credit card payment outfit in the U.S. Will the stock continue its winning streak this year or will tech "disruptors" knock the company off its perch? Read More
John Persinos is the editorial director of Investing Daily, overseeing such publications as Personal Finance, Utility Forecaster, Profit Catalyst Alert, Rapier's Income Accelerator, Income Forecaster, and Marijuana Investing Daily, among others. John also writes the Mind Over Markets daily stock market recap, and he's the chief investment strategist of Marijuana Profit Alert.
John has decades of experience in the technology and political realms. He has worked as a staff editor at Inc. and Venture magazines, and written for Kiplinger's, Street Authority, Investing Answers, and TheStreet.com, to name a few. In a career that has spanned more than 40 years, John has been diligently and prolifically covering the news and its impact on investors.
John also has experience with the inner-workings of Capitol Hill, serving as a press secretary to U.S. Rep. Byron Dorgan (D-ND). John started his career as a daily newspaperman with The Orlando Sentinel.
John holds undergraduate and graduate degrees from Boston University. He also completed the Davenport Fellowship in Business and Economics Reporting at the University of Missouri (Columbia).
Analyst Articles
The rising incidence of hacking dominates the front pages. We examine cybersecurity firm Bravatek to see if it's a growth play or just another risky fad stock. Read More
This mid-cap biotech is developing novel drugs for diseases that resist conventional therapies. Is Arena a future "rocket stock" or will it blow up on the launch pad? Read More
This cannabis biotech is a micro-cap garnering Wall Street's attention. As investors flock to pot investments, is United Cannabis an appealing play or risky penny stock? Read More
Hemp (OTC: HEMP) uses the sturdy fibers of the hemp plant to create industrial products. Is this "picks-and-shovels" cannabis play a worthy investment or risky penny stock? Read More
This maker of cannabis-related recreational and medical products enjoys tailwinds as cannabis legalization continues apace. But is it an overly risky penny stock? Read More
Is this cannabis company a viable enterprise or just another penny stock booby trap? We examine whether Abattis is a small-cap value play or toxic investment. Read More
Florida, with its growing population of retired baby boomers and easy-going subtropical culture, is a thriving mecca for marijuana companies. Cannabis sales are growing quickly throughout the U.S., but pot demand is especially strong in the Sunshine State. This unstoppable multi-year trend explains why Trulieve Cannabis (CSE: TRUL, OTC: TCNNF)… Read More
Marijuana has come a long way from the hackneyed comedy sketches of Cheech & Chong. The escalating legalization of marijuana has given rise to cannabis dispensaries, where marijuana products are sold over the counter just like the products you can buy at your friendly neighborhood CVS. Cannabis dispensaries are local… Read More
Time for a snap quiz. Without using Google or peeking, identify the public figure who made this statement: Federal and state laws (should) be changed to no longer make it a crime to possess marijuana for private use. Cue the theme from Jeopardy. Give up? It was President… Read More